Pre-commercial biopharm is a ride. IMO lots of slack should be cut to all of them. SAVA has a 25 year track record of simply not delivering - it talked up its opioid for over a dozen years and then that failed. Will simufilam be different? Maybe. Hope so. But the same kind of management pumping is in force as before.- at least a yellow light. And the OL data and the short blinded extension data was...no bueno.
Market Data 
Markets 
AI
